Abstract:To the Editor: We read with great interest the article by Lapane et al (1) regarding the effect of shortand long-term use of prescription nonsteroidal antiinflammatory drugs (NSAIDs) on symptoms and structural progression among patients with radiographically confirmed osteoarthritis (OA) of the knee. This prospective observational study suggested that long-term, but not short-term, NSAID use was associated with an a priori–defined minimally important clinical change in stiffness, physical function, and joint space width, but not pain. We appreciate the authors’ work; however, some worthwhile issues need to be explored. The authors classified 12 different kinds of NSAIDs together to assess the effect on knee OA of these drugs as a whole. Every NSAID has distinguishing characteristics with respect to therapeutic effect, safety, and price. For example, results of a recent high-quality network meta-analysis clearly indicated that naproxen, ibuprofen, and diclofenac, but not celecoxib, were statistically significantly superior to acetaminophen in terms of pain relief for patients with knee OA (2). There are 2 main types of NSAIDs: traditional NSAIDs (ibuprofen, naproxen, diclofenac, etc.) and celecoxib (the only selective NSAID currently available in America) (3). We are interested in learning about the results of this subgroup analysis (traditional versus selective NSAIDs). In addition, no information about the NSAID doses was available. The population of NSAID recipients in this study was largely heterogeneous. Consequently, we are not sure whether such conclusions have instructional significance for clinical practice. Aside from the implications for clinical practice, we are also worried about the reliability of the positive conclusion. The authors stated that long-term NSAID use was associated with clinical changes in stiffness, physical function, and joint space width. However, the 95% confidence intervals included 0, which could be interpreted as evidence that there is no real difference between long-term NSAID recipients and nonrecipients and that long-term NSAID use has no effect (4). The authors admitted that the estimates did not reach statistical significance, which indicates that a Type II error may exist. In other words, a significance test failed to identify the real clinical difference. Although the evidence showed that the a priori–defined minimally important clinical change had been reached, the possibility that the positive results of the study were due to chance could not be ruled out. We admit that the clinical significance is of importance, but we would like to emphasize the fact that statistical significance does not ensure truth and careful attention should be paid to false-positive errors. Furthermore, other issues need to be noted. First, the authors indicated that evidence regarding long-term effects of oral NSAIDs is still lacking, and their effect on structural changes in the joint has not been well established. However, the clinical efficacy and safety of celecoxib, as well as the effects of celecoxib on progression of knee OA over 2 years, have been reported previously (5,6). Second, according to the Osteoarthritis Research Society International atlas (7), joint space narrowing and formation of osteophytes should be determined for knee OA. We are curious about why the progression of osteophytes was not assessed. Third, patients in observational studies differ from those in clinical trials by, for example, the wider spectrum of coexisting illness included in observational studies, which could result in a good generalizability (8). However, the multivariable model was not adjusted for certain underlying diseases, such as diabetes mellitus and hypertension. Finally, it should be noted that safety is an extremely important index for assessing oral NSAIDs, especially for long-term use. The authors admitted that discontinuation rates of prescription NSAIDs have been reported to exceed 85% within 6 months of initiation. We would like more information regarding the side effects of NSAID use in this study. We value the contributions of Lapane et al, and we are very interested in the authors’ response to these issues.

Energy considerations in second breakdown

Laparoscopic varicocelectomy with lymphatic preservation using methylene blue dye.

COP-22 Alleviates d-Galactose–Induced Brain Aging by Attenuating Oxidative Stress, Inflammation, and Apoptosis in Mice

Is It Appropriate to Classify All Kinds of Nonsteroidal Antiinflammatory Drugs Together for Assessing the Treatment of Knee Osteoarthritis? Comment on the Article by Lapane et al

Lactiplantibacillus plantarum CCFM8661 alleviates D-galactose-induced brain aging in mice by the regulation of the gut microbiota

Blue native/SDS-PAGE combined with iTRAQ analysis reveals advanced glycation end-product-induced changes of synaptosome proteins in C57 BL/6 mice

Geraniol Attenuates Oxidative Stress and Neuro-inflammation Mediated Cognitive Impairment in D‑galactose‑induced Mouse Aging Model

On the quantification of intertest variability in ecotoxicity data with application to species sensitivity distributions

Cistanche deserticola polysaccharides alleviate cognitive decline in aging model mice by restoring the gut microbiota-brain axis

Ascorbic Acid Mitigates D-galactose-Induced Brain Aging by Increasing Hippocampal Neurogenesis and Improving Memory Function

Lactiplantibacillusplantarum JS19-adjunctly fermented goat milk alleviates D-galactose-induced aging by modulating oxidative stress and intestinal microbiota in mice

Is objective assessment of cosmetic results after distal hypospadias repair superior to subjective assessment?

Chronic Systemic D‐galactose Exposure Induces Memory Loss, Neurodegeneration, and Oxidative Damage in Mice: Protective Effects of R‐α‐lipoic Acid

Codonopsis pilosula water extract delays D-galactose-induced aging of the brain in mice by activating autophagy and regulating metabolism

Lactiplantibacillus plantarum X7022 Plays Roles on Aging Mice with Memory Impairment Induced by D-Galactose Through Restoring Neuronal Damage, Relieving Inflammation and Oxidative Stress

Ergothioneine improves cognitive function through ameliorating mitochondrial damage and decreasing neuroinflammation in a d-galactose-induced aging model

CLIPS – a camera and laser-based indoor positioning system

Gliclazide Ameliorates Neuronal Injury by Attenuating Oxidative Stress in D-gal-Induced Senescent Cells and Aging Mice

Role of D-galactose-induced brain aging and its potential used for therapeutic interventions

Alleviation effects of grape seed proanthocyanidin extract on inflammation and oxidative stress in a D-galactose-induced aging mouse model by modulating the gut microbiota.

Dowling-Degos disease affecting the vulva.